# Cannabis News and Regulatory Roundup:… > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-news-and-regulatory-roundup-substance-use-patterns-in-a-communi-oct-2026/ > **Published:** 2026-10-05T12:31:46-04:00 | **Last Modified / Clinically Audited:** 2026-10-05T15:15:17-04:00 > **Clinical Summary:** cannabis news digest: CED Clinic analysis of 3 recent cannabis policy, science, and regulatory developments with Dr. Benjamin Caplan. --- CED Clinical Relevance #65 Verified Overview Curated multi-source overview preserving 3 verified developments. Clinical Insight | CED Clinic The strongest practical signal here is clustering: more than half of adult women with recent substance use fell into mixed-use patterns, and the mix shifted with age, with heavier alcohol and prescription misuse becoming more prominent in older women while heavy cannabis use was more common in younger cohorts. In adolescents with chronic pain, alcohol use was not rare, and the combination of older age, depression, low perceived risk, and prior cannabis use marked a higher-risk subgroup. That argues for routine, age-tailored screening that asks about frequency, co-use, and motivation, not just whether a substance has ever been tried. It also supports brief counseling that links mood, pain coping, and substance risk in the same visit. DigestCannabis NewsRegulationPublic HealthClinical Practice AudiencePatients, clinicians, healthcare professionals, regulators, and industry researchers. Primary TopicCurated updates on Substance use patterns in a community sample of ad. Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42831068/) Table of Contents - [Cannabis News and Regulatory Roundup: Substance use patterns in a community…](#Cannabis_News_and_Regulatory_Roundup_Substance_use_patterns_in_a_community8230)[How to Interpret This Cannabis News and Regulatory Roundup](#How_to_Interpret_This_Cannabis_News_and_Regulatory_Roundup)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Viewpoints on These Updates](#CED_Perspective_Lens_Eight_Viewpoints_on_These_Updates)[What this means for patients](#What_this_means_for_patients) - [What clinicians should do with this](#What_clinicians_should_do_with_this) - [Safety signals in these studies](#Safety_signals_in_these_studies) - [Policy implications](#Policy_implications) - [What future studies need to answer](#What_future_studies_need_to_answer) - [What to question before overreading this](#What_to_question_before_overreading_this) - [What families and caregivers should notice](#What_families_and_caregivers_should_notice) - [Bottom line](#Bottom_line) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Cannabis News and Regulatory Roundup: Substance use patterns in a community… A structured CED Clinic overview of 3 key developments in [cannabis regulation](https://cedclinic.com/cbd-gummies-lung-issues/), market milestones, and scientific research. What This Study Teaches Us In a community sample of 2,296 U.S. women ages 18 to 70 who reported substance use in the prior 30 days, heavy cannabis use, defined as 16 or more days per month, was common at about 22%, and heavy alcohol use was about 18%. Latent class analysis found four patterns: alcohol use with some cannabis (57%), heavy cannabis with some alcohol (27%), polysubstance use (10%), and prescription medication misuse with some alcohol (6%), with heavy alcohol and prescription misuse rising in older cohorts while heavy cannabis declined. In 243 adolescents ages 14 to 19 with chronic pain from a tertiary pain clinic, lifetime alcohol use was 32.1%, past-year use 30.45%, and past-month use 16.46%. Older age, depressive symptoms, and behavioral approach predicted lifetime alcohol use, and low perceived risk was strongly associated with more frequent past-year use, with odds ratios ranging from 7.13 to 91.60; lifetime cannabis use was also associated with higher past-year alcohol frequency (OR 5.71). Why This Matters These data point to age-specific substance use patterns that matter for screening, because cannabis, alcohol, and prescription misuse do not cluster the same way across life stages. That changes what to ask about, how to counsel, and where to look for hidden risk, especially in women and in adolescents with chronic pain. The adolescent pain cohort is a reminder that low risk perception and depressed mood can drive alcohol use even when pain is the presenting problem. In practice, that means harm reduction conversations should include alcohol, cannabis, and prescription medications together, not as separate silos. Study SnapshotPost TypeCannabis News and Regulatory Roundup using canonical CED layoutItems Reviewed3 verified updatesPrimary DatesOctober 05, 2026Related Reading3 verified live CED Clinic internal linksStudy 1Substance use patterns in a community sa (Greenfield et al., Addictive behaviors reports) [DOI: 10.1016/j.abrep.2026.100748 | PMID: 42831068]Study 2Alcohol use in adolescent chronic pain: (Koike et al., Drug and alcohol dependence reports) [DOI: 10.1016/j.dadr.2026.100481 | PMID: 42830988]Study 3Veteran prescribed ‘ghastly’ amount of c (Google Alert Cannabis 05 et al., Google Alert Cannabis 05) Clinical Bottom Line This cannabis news and regulatory roundup preserves key signals across 3 updates without overstatement, offering grounded guidance for patients and practitioners. Digest Contents - [Digest Card 1 | Substance use patterns in a community sample of ad](#digest-card-2-digest-card-1-substance-use-patterns-in-a-community-sample-of-ad) - [Digest Card 2 | Alcohol use in adolescent chronic pain: Prevalence](#digest-card-3-digest-card-2-alcohol-use-in-adolescent-chronic-pain-prevalence) - [Digest Card 3 | Veteran prescribed 'ghastly' amount of cannabis by](#digest-card-4-digest-card-3-veteran-prescribed-ghastly-amount-of-cannabis-by) Why These 3 Updates Belong Together This curated cannabis news and regulatory roundup brings together 3 key developments across policy, market milestones, and health regulations. Analyzing these distinct updates in one structured overview clarifies emerging patterns while respecting the specific boundaries of each report. Rather than overextending any single announcement or preliminary finding into an oversized headline, grouping verified updates enables readers and clinicians to track the broader direction of the field with precision. Digest Card 1 | Substance use patterns in a community sample of ad **Title & Source:** [Substance use patterns in a community sample of adult women in the United States: Alcohol, Cannabis, and other drug use.](https://pubmed.ncbi.nlm.nih.gov/42831068/) (*Addictive behaviors reports*, 2026Dec) **Lead Authors & Identifiers:** Shelly F Greenfield, Allen J Bailey, Laura C Seidman, Dawn E Sugarman et al.. | **Primary Record:** DOI: 10.1016/j.abrep.2026.100748 | PMID: 42831068 Content lane: **Evidence Check**. **1. Scientific & Clinical Background:** This was a cross-sectional online survey of 2,296 adult women ages 18 to 70 in the U.S. community who reported substance use in the prior 30 days. The investigators used latent class analysis to identify patterns across alcohol, cannabis, other drugs, and prescription medication misuse. **2. Detailed Findings & Primary Data:** Heavy use was common, with approximately 18% heavy alcohol use and 22% heavy cannabis use. Four classes emerged: alcohol use with some cannabis (57%), heavy cannabis with some alcohol (27%), polysubstance use (10%), and prescription medication misuse with some alcohol (6%). Heavy alcohol use and prescription medication misuse increased with older age cohort, while heavy cannabis use decreased with age. **3. Dr. Caplan’s Clinical & Practical Guidance:** This supports asking adult women about multiple substances together, not just one at a time, because mixed-use patterns were the norm. Age should shape counseling, since older women in this sample were more likely to show heavy alcohol use and prescription misuse, while younger women more often clustered around heavier cannabis use. **4. Study Boundaries & Methodological Limits:** The sample only included women who had used substances in the prior 30 days, so it is not a general population estimate. Self-report and cross-sectional design limit precision about dose, timing, and causality. Digest Card 2 | Alcohol use in adolescent chronic pain: Prevalence **Title & Source:** [Alcohol use in adolescent chronic pain: Prevalence rates, perceptions of risk, and predictors of use.](https://pubmed.ncbi.nlm.nih.gov/42830988/) (*Drug and alcohol dependence reports*, 2026Dec) **Lead Authors & Identifiers:** Camila Koike, Nicole Tacugue, Erin Sands, Elissa R Weitzman et al.. | **Primary Record:** DOI: 10.1016/j.dadr.2026.100481 | PMID: 42830988 Content lane: **Evidence Check**. **1. Scientific & Clinical Background:** This cross-sectional survey studied 243 adolescents ages 14 to 19 with chronic pain from a tertiary pediatric pain clinic. The goal was to estimate alcohol use prevalence and identify biopsychosocial correlates, including mood, risk perception, and cannabis use. **2. Detailed Findings & Primary Data:** Lifetime alcohol use was 32.1%, past-year use 30.45%, and past-month use 16.46%. Older age, higher depressive symptoms, and behavioral approach predicted lifetime alcohol use, while low perceived risk was associated with much higher odds of more frequent past-year use, with ORs ranging from 7.13 to 91.60; lifetime cannabis use was associated with higher past-year alcohol frequency (OR 5.71). **3. Dr. Caplan’s Clinical & Practical Guidance:** In adolescents with chronic pain, alcohol screening should be routine and should include depression and risk perception, not just substance history. A history of cannabis use should raise attention to broader co-use patterns and prompt a more careful harm-reduction discussion. **4. Study Boundaries & Methodological Limits:** This was a single-clinic tertiary sample, so the prevalence and predictors may not generalize to all adolescents with chronic pain. The cross-sectional design cannot determine whether depression, cannabis use, or low risk perception preceded alcohol use. Digest Card 3 | Veteran prescribed ‘ghastly’ amount of cannabis by **Title & Source:** [Veteran prescribed ‘ghastly’ amount of cannabis by for-profit health company – ABC News](https://www.abc.net.au/news/2026-10-05/veteran-prescribed-ghastly-amount-of-cannabis/107228410) (*Google Alert Cannabis 05*, 2026-10-05T10:19:06+00:00) **Lead Authors & Identifiers:** Google Alert Cannabis 05. Content lane: **Research Brief**. **1. Scientific & Clinical Background:** This item is a news headline rather than a scientific study, and no methods, cohort, or outcomes are provided in the supplied material. It cannot be evaluated the way the two PubMed studies can. **2. Detailed Findings & Primary Data:** No quantitative findings are available in the published report. There are no sample sizes, endpoints, or statistical results to synthesize from the headline alone. **3. Dr. Caplan’s Clinical & Practical Guidance:** A headline can flag a policy or safety concern, but it should not be treated as evidence without the underlying reporting or primary source. Clinical decisions should rest on the actual data, not the framing of a media story. **4. Study Boundaries & Methodological Limits:** Because no primary study details are provided, there is nothing to appraise for validity or generalizability. It should be excluded from evidence-based synthesis beyond noting that it is not a research paper. How Strong Is This Evidence? Both studies are cross-sectional and observational, but the sample sizes are respectable for pattern detection, especially the 2,296-woman community survey. The latent class analysis in the adult study adds useful structure, while the adolescent pain study provides clinically relevant odds ratios from a defined tertiary-care cohort. The evidence is stronger for describing prevalence and associations than for proving causation. The adult study is broader and more generalizable within women who used substances recently, while the adolescent study is more clinically specific but narrower because it comes from one specialty pain clinic. Where This Paper Deserves Skepticism Both studies rely on self-report, which can undercount stigmatized use and blur timing, dose, and co-use. Cross-sectional design also means the observed associations, especially depression, cannabis use, and alcohol frequency, cannot tell us what came first. The adult survey only included women who reported substance use in the prior 30 days, so it does not represent all adult women. The adolescent pain sample comes from a tertiary clinic, which likely enriches for more severe pain, more comorbidity, and different substance use risk than community adolescents. What This Paper Does Not Show These papers do not show that cannabis or alcohol caused worse pain, depression, or later substance problems. They also do not establish that one screening or counseling approach will reduce use or improve outcomes. They do not define safe thresholds for co-use, nor do they tell us which specific interventions work best for older women, younger women, or adolescents with chronic pain. The ABC News item is not a scientific study and does not add empirical evidence. How This Fits With the Broader Clinical Conversation These findings fit a broader shift in [cannabis medicine](https://cedclinic.com/cbd-gummies-smoking-cessation/) toward looking at real-world co-use patterns, not isolated products or single-substance exposure. That matters because many patients use cannabis alongside alcohol, nicotine, or prescription medications, and the clinical risk often comes from the combination rather than any one agent alone. The adolescent pain data also align with growing concern that pain clinics are becoming important touchpoints for early substance risk detection. As cannabis access expands and alcohol remains common, clinicians are being pushed toward integrated screening that includes mood, pain coping, and family context, rather than treating each issue separately. Editorial Commentary *What stands out is not just how common use is, but how differently it presents across ages and settings. In adult women, the pattern is often mixed use, and in older cohorts the signal shifts toward alcohol and prescription misuse. In adolescents with chronic pain, alcohol use is already present for a meaningful minority, and the strongest clues are depression, low perceived risk, and prior cannabis exposure.* *That is useful because it changes the conversation. A patient who says they use cannabis a few nights a week may also be drinking more than they mention, and a teen with chronic pain who seems focused on symptom relief may be using alcohol as part of a broader coping pattern. The practical move is to ask about frequency, co-use, and mood in the same breath, then tailor advice to the person in front of you.* What a Careful Reader Should Take Away Screen for cannabis, alcohol, and prescription misuse together, and pay special attention to age, mood, and perceived risk. These studies support targeted counseling, not assumptions about who is or is not at risk. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about these updates:[🛡️Use Disorder](https://cedclinic.com/ask)[💢Pain](https://cedclinic.com/ask)[🧠Anxiety and Mood](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Cannabis News and Regulatory Roundup These papers are most useful as pattern maps, not outcome trials. They show who is using what, how often, and in what combinations, which is exactly the information needed to improve screening and harm reduction. ### Three Rules for Critical Reading **1. Separate prevalence from causation**The adult women study describes four use classes in 2,296 recent users, and the adolescent pain study identifies predictors of alcohol use in 243 patients, but neither can prove that one substance caused another outcome. Read the odds ratios and class proportions as risk markers, not as proof of mechanism. **2. Ask who was actually studied**The adult sample included women ages 18 to 70 who had used substances in the prior 30 days, while the adolescent sample came from a tertiary chronic pain clinic. Those choices make the findings clinically relevant, but they also limit how far you can generalize to all women or all teens. **3. Look for co-use and context, not single-substance thinking**More than half of the adult women fell into mixed-use classes, and adolescents with lifetime cannabis use had higher past-year alcohol frequency. The practical lesson is to ask about alcohol, cannabis, and prescription medications together, plus mood and risk perception, because the clinical risk often sits in the combination. Key Evaluation Question Do these data describe a clinically meaningful pattern in a defined population, or do they overreach into claims about causation and treatment effect? The Patient Question If I use cannabis, alcohol, or prescription medications, what should I be watching for in terms of co-use, mood changes, or signs that my pattern is becoming risky? The Bottom Line These studies support better screening and counseling, but they do not prove that any one substance is the cause of the observed risk patterns. CED Perspective Lens ## CED Perspective Lens: Eight Viewpoints on These Updates Why these developments matter across clinical, patient, safety, and policy perspectives Lens OverviewEight distinct clinical and regulatory perspectives on Substance use patterns in a community sample . #### What this means for patients If you use cannabis, alcohol, or prescription medications, these studies suggest the pattern matters as much as the product. In adult women, mixed use was common, and in teens with chronic pain, alcohol use clustered with depression, low risk perception, and prior cannabis use. That means a useful conversation is not just, “Do you use it?” but, “How often, with what else, and why?” The safest next step is honest screening, especially if mood, sleep, pain, or stress are part of the reason for use. Lens takeawayAsk about co-use, mood, and frequency, not just whether you use cannabis. #### What clinicians should do with this The adult women data support age-tailored screening for alcohol, cannabis, and prescription misuse together, because the dominant pattern was mixed use and the mix changed across cohorts. The adolescent pain data support adding depression and risk perception to routine substance screening in pain clinics. A brief, structured history can capture most of the signal: days per month, co-use, perceived risk, and whether the patient is using substances to manage pain, sleep, or mood. That is more actionable than a binary yes or no. Lens takeawayUse structured, age-specific screening that includes co-use and mood. to help evaluate realistic outcomes and safe next steps. #### Safety signals in these studies The main safety signal is not a single substance, but clustering. Heavy cannabis use, heavy alcohol use, and prescription medication misuse appeared together in meaningful subgroups, and low risk perception was linked to more frequent alcohol use in adolescents with chronic pain. That combination raises concern for impaired judgment, additive sedation, and escalation over time, especially when patients are self-treating pain or distress. The data support early harm-reduction counseling before patterns become entrenched. Ongoing post-market surveillance, third-party laboratory verification, and standardized adverse-event reporting remain critical safeguards for identifying rare or delayed toxicity signals. Lens takeawayCo-use and low risk perception are the clearest safety flags here. #### Policy implications These findings argue for integrated screening in primary care, women’s health, and pediatric pain settings, rather than separate substance-use workflows for each drug class. The age differences also support prevention messaging that is tailored by life stage instead of one-size-fits-all education. For cannabis policy, the practical point is that access and normalization do not eliminate co-use risk. Systems that expand availability should still fund screening, brief intervention, and referral pathways for alcohol and prescription misuse. Consistent administrative oversight, clear statutory definitions, and transparent regulatory frameworks ensure that public health protections keep pace with evolving consumer formulations. Lens takeawayPolicy should support integrated screening, not substance-specific silos. to help evaluate realistic outcomes and safe next steps. #### What future studies need to answer The next step is longitudinal work that can track whether depression, cannabis use, and low risk perception predict later alcohol escalation in adolescents with chronic pain. In adult women, it would help to know whether the latent classes remain stable over time and whether they predict treatment engagement or adverse outcomes. Both studies would be stronger with objective measures, repeated assessments, and more diverse sampling. That would clarify whether the observed patterns are durable, modifiable, and clinically meaningful beyond self-report snapshots. Lens takeawayLongitudinal, objective, and more diverse studies are needed next. to help evaluate realistic outcomes and safe next steps. #### What to question before overreading this The adult survey is limited to recent users, so it may inflate the appearance of heavy use compared with the broader population of women. The adolescent study comes from a tertiary pain clinic, which likely selects for more severe illness and higher psychosocial burden. Both are self-report, cross-sectional datasets, so the strongest claims are about association and prevalence, not causation. The very large odds ratios for low risk perception should be read carefully, because they may reflect small subgroup counts or model instability. Lens takeawayTreat the associations as useful signals, not proof of cause. #### What families and caregivers should notice For parents and caregivers, the adolescent study says that chronic pain does not protect against alcohol use, and mood matters. A teen who seems to be coping with pain may also be using alcohol or cannabis in ways that are easy to miss unless someone asks directly. For families of adult women, the mixed-use pattern is the key issue. If alcohol, cannabis, and pills are all in the picture, the risk conversation should include sleep, driving, falls, and medication interactions, not just intoxication. Lens takeawayWatch for mixed use, mood changes, and hidden coping behaviors. #### Bottom line These studies show that cannabis and alcohol rarely live in isolation, especially in women and in adolescents with chronic pain. The clinically useful move is to screen for patterns, not just substances, and to pay attention to age, mood, and perceived risk. That approach is more likely to catch harm early and less likely to miss the patients who are quietly combining substances to manage pain, stress, or sleep. Evaluating primary scientific data with clinical discipline ensures that therapeutic decisions remain balanced, evidence-informed, and grounded in reproducible outcomes. Lens takeawayScreen for patterns, because that is where the risk usually hides. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+News+and+Regulatory+Roundup%3A+Substance+use+patterns+in+a+community...&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-substance-use-patterns-in-a-communi-oct-2026%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-substance-use-patterns-in-a-communi-oct-2026%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+News+and+Regulatory+Roundup%3A+Substance+use+patterns+in+a+community...%20https%3A%2F%2Fcedclinic.com%2Fcannabis-news-and-regulatory-roundup-substance-use-patterns-in-a-communi-oct-2026%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Sources: Addictive behaviors reports, Drug and alcohol dependence reports, Google Alert Cannabis 05](https://pubmed.ncbi.nlm.nih.gov/42831068/) Related Reading at CED ClinicContinue exploring the evidence[Cannabinoids for Low Back Pain and Migraine: What Randomized Trials Actually Show](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/) More on this topic: Rigorous physician appraisal of randomized trials investigating cannabinoid efficacy for chronic pain and migraines. [More on this topic: Chronic pain & migraine](https://cedclinic.com/ced-cannabinoids-for-low-back-pain-and-2026-09-23/)[Adolescent Cannabis Use and Its Impact on Cognitive Development: Insights from the ABCD Study](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/) More on this topic: Long-term ABCD study findings on adolescent brain development, executive function, and early cannabis susceptibility. [More on this topic: Adolescent brain health](https://cedclinic.com/adolescent-cannabis-use-cognitive-development-risk/)[PP-01 for Cannabis Withdrawal: What a 14-Person Trial Found](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/) More on this topic: Clinical trial data evaluating pharmacological interventions and supportive care for cannabis withdrawal. [More on this topic: Withdrawal management](https://cedclinic.com/pp01-cannabis-withdrawal-proof-of-concept/) ## Frequently Asked Questions What is covered in this cannabis news and regulatory roundup? This edition reviews 3 verified developments across cannabis policy, regulatory oversight, and clinical science. How are stories selected for CED digests? Stories are curated from official primary sources, government agency dockets, and peer-reviewed journals, focusing on practical relevance for patients and clinicians. Do preliminary reports establish medical efficacy? No. Observational reports, preprints, and regulatory filings describe emerging trends and require formal clinical trials before treatment efficacy can be claimed. How should clinicians use these updates? Clinicians can use these updates to understand patient questions, stay current with state regulations, and maintain evidence-informed counseling. Where can readers find Dr. Caplan's clinical insights? Dr. Caplan provides comprehensive clinical perspectives, patient consultations, and educational resources at CEDclinic.com. Why are multi-topic digests published instead of single stories? Digests group related updates together to provide a broader thematic overview while preserving important nuances and methodological limits. What is the primary role of laboratory testing in cannabis policy? Laboratory testing verifies cannabinoid potency and screens for harmful contaminants like heavy metals, pesticides, and molds to protect consumer health. How do state regulatory milestones impact [patient access](https://cedclinic.com/tsa-rules-on-cbd-gummies-travel-guidelines-2026/)? Administrative milestones establish the licensing rules, product categories, and retail standards that determine how and where registered patients obtain care. What precautions should families take with [medical cannabis](https://cedclinic.com/cbd-gummies-for-sexual-enhancement-evidence/) at home? Families should keep all medical cannabis products securely locked in child-resistant containers and clearly labeled to avoid accidental exposure. How often does CED Clinic publish clinical and policy updates? CED Clinic publishes regular morning, afternoon, and evening evidence reviews and news digests to keep the community informed. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).